Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
Year of publication
2018
Authors
Purmonen, Timo; Puolakka, Kari; Bhattacharyya, Devarshi; Jain, Minal; Martikainen, Janne
Organizations and authors
Helsinki University Hospital Catchment Area
Puolakka Kari
University of Eastern Finland
Martikainen Janne
Publication type
Publication format
Article
Parent publication type
Journal
Article type
Original article
Audience
ScientificPeer-reviewed
Peer-ReviewedMINEDU's publication type classification code
A1 Journal article (refereed), original researchPublication channel information
Parent publication name
Volume
16
Pages
56
ISSN
Publication forum
Publication forum level
1
Open access
Open access in the publisher’s service
Yes
Open access of publication channel
Fully open publication channel
Self-archived
Yes
Other information
Fields of science
Pharmacy; Public health care science, environmental and occupational health
Keywords
Biologics; Cost-effectiveness; DOUBLE-BLIND; ECONOMIC-EVALUATION; Etanercept; EUROPEAN LEAGUE; FUTURE 2; health; Incremental cost effectiveness ratio; Infliximab; PHARMACOLOGICAL THERAPIES; Psoriatic arthritis; Quality adjusted life years; rheumatoid-arthritis; secukinumab; Treatment recommendations
Internationality of the publisher
International
Language
English
International co-publication
Yes
Co-publication with a company
Yes
DOI
10.1186/s12962-018-0162-3
The publication is included in the Ministry of Education and Culture’s Publication data collection
Yes